Developer docs
API playgroundTry for free, no card

Search company profiles

Asabys Partners

Full company profile

uuid00000nj

Namestring
Asabys Partners
Legal namestring
Sabadell Asabys Health Innovation Investments, S.A.
Websiteurl
asabys.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Asabys Partners is a Barcelona-based venture capital firm founded in 2018 and legally constituted as Sabadell Asabys Health Innovation Investments, S.A. The firm invests exclusively in healthcare and life-sciences innovation, targeting early-stage to clinical-stage companies across biotech, medical devices, digital health, diagnostics and healthcare services in Europe (with a Barcelona/Spain concentration) and selectively in the US, Israel, Belgium and Australia. Its portfolio of more than twenty companies is anchored by Spanish academic spin-offs from IRB Barcelona, ICREA, VHIO and the Centre for Genomic Regulation, and spans therapeutic platforms (e.g., Ona Therapeutics' ADCs, Oriva Therapeutics' women's-health pipeline, Peptomyc's MYC inhibitor OMO-103, Nuage, Augustine, Accure), medical devices (SafeHeal Colovac, Inbrain Neuroelectronics, Anaconda, Medasense), diagnostics (DeepUll, Binx Health, Quibim), digital therapeutics (XRHealth, Sidekick, Mediktor) and care services (Qida).

The firm's go-to-market is direct institutional investing: sourcing deals through its proprietary network and Spanish research institutes, conducting technical and commercial due diligence, and deploying capital alongside co-investors while acting as a hands-on partner to portfolio companies. Capital is raised and deployed through multiple vehicles, most prominently the Sabadell Asabys II fund and the Asabys Innvierte Tech Transfer fund (a €63.5M vehicle backed by CDTI's Innvierte program). LPs include Banco Sabadell, Alantra, the European Investment Bank and EU EFSI, ICO, Institut Català de Finances, Generalitat Valenciana and Institut Valencià de Finances. Revenue mechanics follow the standard European venture model: management fees on committed or invested AUM across funds, plus carried interest realized through IPOs, M&A exits and secondary sales (e.g., the Agomab acquisition of Origo Biopharma in 2021 and the merger of Amelia Virtual Care into XRHealth in 2023). Asabys aligns investment processes with UN Sustainable Development Goals and integrates ESG considerations, and is operated by a 15-person team led by co-founders Josep Ll. Sanfeliu and Clara Campàs.

Short descriptiontext

Asabys Partners is a Barcelona-based venture capital firm founded in 2018 that invests exclusively in early- to clinical-stage healthcare and life-sciences companies across Europe, primarily through its Sabadell Asabys II fund and the CDTI-backed Asabys Innvierte Tech Transfer vehicle, backing more than 20 biotech, medtech, diagnostics and digital health portfolio companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, healthcare venture capital, biotech investment, life sciences funding, medtech investment
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • All Other Financial Investment Activities52399
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Healthcare Investment
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns and Management Fees
TypeLicensing Royalties
Description

As a venture capital firm, Asabys generates returns through equity appreciation in portfolio companies, carried interest on successful exits, and management fees from funds under management. Revenue is realized through IPOs, acquisitions, or secondary sales of portfolio company equity.

asabys.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Sabadell Asabys II
Description

Venture capital fund managed by Asabys Partners focused on healthcare and life sciences investments

asabys.com
+1 more record
Core offering1 text field

Asabys Partners is a Barcelona-based venture capital firm that invests in early-stage and growth-stage healthcare and life-sciences companies across biotech, healthtech, and medtech. It manages investment vehicles including the Sabadell Asabys II fund and the Asabys Innvierte Tech Transfer vehicle, deploying capital alongside hands-on operational partnership to portfolio companies in Europe and beyond.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Asabys Partners is a Barcelona-based venture capital firm (Sabadell Asabys II fund) investing in healthcare and life-sciences innovation across Europe. The firm does not operate a single unified product; instead it manages a portfolio of 22+ portfolio companies spanning biotech, healthtech, and medtech sectors. The portfolio is organized around disruptive therapeutic and diagnostic platforms including: Ona Therapeutics (first-in-class ADCs for breast cancer), Oriva Therapeutics (women's health: endometriosis and uterine fibroids), Orikine Bio (Foldikine cytokine engineering platform), Peptomyc (MYC mini-protein inhibitors), Nuage Therapeutics (intrinsically disordered protein inhibitors), ALLOX (allosteric drug discovery platform), Accure Therapeutics (CNS disease modifiers), Augustine Therapeutics (HDAC6 inhibitors), Agomab Therapeutics (growth factor/fibrosis programs), Splice Bio (intein-based gene therapy), Inbrain Neuroelectronics (graphene brain-machine interfaces), XRHealth/Ame (extended reality therapeutic platform combining VR/AR, licensed clinicians, and data analytics), Mediktor (AI-powered medical triage assistant), Quibim (AI-driven imaging biomarker platform with regulatory-cleared devices integrated into Philips MR scanners), Medasense (AI-based objective pain monitoring), Binx Health (FDA-cleared point-of-care molecular diagnostics), DeepUll (culture-free sepsis diagnostics), SafeHeal Colovac (endoluminal bypass device for colorectal surgery), Anaconda (thrombectomy systems for ischemic stroke), Gradient Denervation (ultrasound catheter for pulmonary hypertension), Inbiomotion (MAF biomarker for bone metastasis stratification), Sidekick (gamified digital therapeutics), and Qida (B Corp home care services). The investment strategy emphasizes first-in-class and best-in-class technologies with high unmet medical need, hands-on operational partnership, and alignment with ESG and UN Sustainable Development Goals.

Product and service1 record
1Sabadell Asabys II Fund
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

Spin-off partner contributing two advanced assets (ORV-362 and ORV-499) to Oriva Therapeutics for women's health therapies.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

Spin-off partner contributing assets to Oriva Therapeutics for women's health drug development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spanish-based venture capital firm specializing in life sciences and biotech, with comparable Spain/European focus and participation in many of the same syndicates as Asabys (e.g., Ona Therapeutics).

TypeDirect peer
Description

One of Europe's largest healthcare and life-sciences VCs, investing across biotech, medtech and digital health from early to late stage. Directly comparable as a sector specialist serving European healthcare innovation.

TypeDirect peer
Description

European healthcare-focused VC managing multi-billion-euro funds, investing in biotech and medtech from Series A to late stage. Directly comparable as a healthcare sector specialist operating across Europe.

TypeDirect peer
Description

Spain-based venture capital firm focused on life sciences and biotechnology, frequently co-investing alongside Asabys (e.g., leading Ona Therapeutics' Series B). A close direct peer in the Spanish healthcare VC ecosystem.

TypeDirect peer
Description

European healthcare-dedicated investment firm backing biotech, diagnostics and medtech. Co-led rounds alongside Asabys and shares a similar European, healthcare-only mandate.

6Panakès Partners
TypeDirect peer
Description

Italian-based venture capital investor in medical technologies, digital health and biotech. Co-invested with Asabys in deepull's Series C and shares a similar early-to-growth stage healthcare focus in Southern Europe.

TypeDirect peer
Description

Dutch VC firm with a dedicated healthcare and life sciences strategy, investing in early-to-growth stage European biotech and healthtech companies. Comparable as a sector-focused European healthcare VC.

8EQT Life Sciences (formerly LSP)
TypeBroad incumbent
Description

Large pan-European life sciences investor within the broader EQT platform, investing across all stages of healthcare. Comparable in mandate but materially larger in AUM and stage range.

TypeBroad incumbent
Description

French public investment bank with large healthcare and life sciences investment activities across all stages. Overlapping as an LP/co-investor in several Asabys portfolio companies (e.g., Ona Therapeutics).

10CDTI (Centro para el Desarrollo Tecnológico e Industrial)
TypeOthers
Description

Spanish public innovation funding body that commits capital to tech-transfer funds (e.g., €63.5M to Asabys Innvierte Tech Transfer) and co-invests in portfolio companies. Closely related as an LP/co-investor rather than a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment43 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Asabys Partners

Venture Capital / Healthcare Investmentasabys.com

Asabys Partners is a Barcelona-based venture capital firm founded in 2018 that invests exclusively in early- to clinical-stage healthcare and life-sciences companies across Europe, primarily through its Sabadell Asabys II fund and the CDTI-backed Asabys Innvierte Tech Transfer vehicle, backing more than 20 biotech, medtech, diagnostics and digital health portfolio companies.

What Asabys Partners does

Asabys Partners is a Barcelona-based venture capital firm founded in 2018 and legally constituted as Sabadell Asabys Health Innovation Investments, S.A. The firm invests exclusively in healthcare and life-sciences innovation, targeting early-stage to clinical-stage companies across biotech, medical devices, digital health, diagnostics and healthcare services in Europe (with a Barcelona/Spain concentration) and selectively in the US, Israel, Belgium and Australia. Its portfolio of more than twenty companies is anchored by Spanish academic spin-offs from IRB Barcelona, ICREA, VHIO and the Centre for Genomic Regulation, and spans therapeutic platforms (e.g., Ona Therapeutics' ADCs, Oriva Therapeutics' women's-health pipeline, Peptomyc's MYC inhibitor OMO-103, Nuage, Augustine, Accure), medical devices (SafeHeal Colovac, Inbrain Neuroelectronics, Anaconda, Medasense), diagnostics (DeepUll, Binx Health, Quibim), digital therapeutics (XRHealth, Sidekick, Mediktor) and care services (Qida).

The firm's go-to-market is direct institutional investing: sourcing deals through its proprietary network and Spanish research institutes, conducting technical and commercial due diligence, and deploying capital alongside co-investors while acting as a hands-on partner to portfolio companies. Capital is raised and deployed through multiple vehicles, most prominently the Sabadell Asabys II fund and the Asabys Innvierte Tech Transfer fund (a €63.5M vehicle backed by CDTI's Innvierte program). LPs include Banco Sabadell, Alantra, the European Investment Bank and EU EFSI, ICO, Institut Català de Finances, Generalitat Valenciana and Institut Valencià de Finances. Revenue mechanics follow the standard European venture model: management fees on committed or invested AUM across funds, plus carried interest realized through IPOs, M&A exits and secondary sales (e.g., the Agomab acquisition of Origo Biopharma in 2021 and the merger of Amelia Virtual Care into XRHealth in 2023). Asabys aligns investment processes with UN Sustainable Development Goals and integrates ESG considerations, and is operated by a 15-person team led by co-founders Josep Ll. Sanfeliu and Clara Campàs.

Asabys Partners firmographics

Firmographics
Name
Asabys Partners
Legal name
Sabadell Asabys Health Innovation Investments, S.A.
Website
https://asabys.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Asabys Partners is a Barcelona-based venture capital firm founded in 2018 that invests exclusively in early- to clinical-stage healthcare and life-sciences companies across Europe, primarily through its Sabadell Asabys II fund and the CDTI-backed Asabys Innvierte Tech Transfer vehicle, backing more than 20 biotech, medtech, diagnostics and digital health portfolio companies.
Ownership category
akta.pro rank

Asabys Partners industry classification

Industry
Product category
Venture Capital / Healthcare Investment
NAICS
Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital investing
  • Healthcare venture capital
  • Biotech investment
  • Life sciences funding
  • Medtech investment

Where Asabys Partners is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Asabys Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Investment Returns and Management Fees: As a venture capital firm, Asabys generates returns through equity appreciation in portfolio companies, carried interest on successful exits, and management fees from funds under management. Revenue is realized through IPOs, acquisitions, or secondary sales of portfolio company equity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Asabys Partners product offering

Product offering

Core offering

Asabys Partners is a Barcelona-based venture capital firm that invests in early-stage and growth-stage healthcare and life-sciences companies across biotech, healthtech, and medtech. It manages investment vehicles including the Sabadell Asabys II fund and the Asabys Innvierte Tech Transfer vehicle, deploying capital alongside hands-on operational partnership to portfolio companies in Europe and beyond.

Product overview

Asabys Partners is a Barcelona-based venture capital firm (Sabadell Asabys II fund) investing in healthcare and life-sciences innovation across Europe. The firm does not operate a single unified product; instead it manages a portfolio of 22+ portfolio companies spanning biotech, healthtech, and medtech sectors. The portfolio is organized around disruptive therapeutic and diagnostic platforms including: Ona Therapeutics (first-in-class ADCs for breast cancer), Oriva Therapeutics (women's health: endometriosis and uterine fibroids), Orikine Bio (Foldikine cytokine engineering platform), Peptomyc (MYC mini-protein inhibitors), Nuage Therapeutics (intrinsically disordered protein inhibitors), ALLOX (allosteric drug discovery platform), Accure Therapeutics (CNS disease modifiers), Augustine Therapeutics (HDAC6 inhibitors), Agomab Therapeutics (growth factor/fibrosis programs), Splice Bio (intein-based gene therapy), Inbrain Neuroelectronics (graphene brain-machine interfaces), XRHealth/Ame (extended reality therapeutic platform combining VR/AR, licensed clinicians, and data analytics), Mediktor (AI-powered medical triage assistant), Quibim (AI-driven imaging biomarker platform with regulatory-cleared devices integrated into Philips MR scanners), Medasense (AI-based objective pain monitoring), Binx Health (FDA-cleared point-of-care molecular diagnostics), DeepUll (culture-free sepsis diagnostics), SafeHeal Colovac (endoluminal bypass device for colorectal surgery), Anaconda (thrombectomy systems for ischemic stroke), Gradient Denervation (ultrasound catheter for pulmonary hypertension), Inbiomotion (MAF biomarker for bone metastasis stratification), Sidekick (gamified digital therapeutics), and Qida (B Corp home care services). The investment strategy emphasizes first-in-class and best-in-class technologies with high unmet medical need, hands-on operational partnership, and alignment with ESG and UN Sustainable Development Goals.

Differentiator

Problem solved

Functional benefit

Brands

  • Sabadell Asabys II: Venture capital fund managed by Asabys Partners focused on healthcare and life sciences investments
  • Asabys Innvierte Tech Transfer

Products and services

  • Sabadell Asabys II Fund

Companies that use Asabys Partners

Customer profile

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Asabys Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Asabys Partners partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered supporting.

  • OncostellaesupportingStrategic or Co-development Partner · 22 January 2026Spin-off partner contributing two advanced assets (ORV-362 and ORV-499) to Oriva Therapeutics for women's health therapies.
  • MedibiofarmasupportingStrategic or Co-development Partner · 22 January 2026Spin-off partner contributing assets to Oriva Therapeutics for women's health drug development.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Asabys Partners competitors and assessment

Company assessment

Direct peers

  • Ysios Capital: Spanish-based venture capital firm specializing in life sciences and biotech, with comparable Spain/European focus and participation in many of the same syndicates as Asabys (e.g., Ona Therapeutics).
  • Sofinnova Partners: One of Europe's largest healthcare and life-sciences VCs, investing across biotech, medtech and digital health from early to late stage. Directly comparable as a sector specialist serving European healthcare innovation.
  • Forbion: European healthcare-focused VC managing multi-billion-euro funds, investing in biotech and medtech from Series A to late stage. Directly comparable as a healthcare sector specialist operating across Europe.
  • Columbus Venture Partners: Spain-based venture capital firm focused on life sciences and biotechnology, frequently co-investing alongside Asabys (e.g., leading Ona Therapeutics' Series B). A close direct peer in the Spanish healthcare VC ecosystem.
  • Mérieux Equity Partners: European healthcare-dedicated investment firm backing biotech, diagnostics and medtech. Co-led rounds alongside Asabys and shares a similar European, healthcare-only mandate.
  • Panakès Partners: Italian-based venture capital investor in medical technologies, digital health and biotech. Co-invested with Asabys in deepull's Series C and shares a similar early-to-growth stage healthcare focus in Southern Europe.
  • Inkef Capital: Dutch VC firm with a dedicated healthcare and life sciences strategy, investing in early-to-growth stage European biotech and healthtech companies. Comparable as a sector-focused European healthcare VC.

Broad incumbents

  • EQT Life Sciences (formerly LSP): Large pan-European life sciences investor within the broader EQT platform, investing across all stages of healthcare. Comparable in mandate but materially larger in AUM and stage range.
  • Bpifrance: French public investment bank with large healthcare and life sciences investment activities across all stages. Overlapping as an LP/co-investor in several Asabys portfolio companies (e.g., Ona Therapeutics).

Others

  • CDTI (Centro para el Desarrollo Tecnológico e Industrial): Spanish public innovation funding body that commits capital to tech-transfer funds (e.g., €63.5M to Asabys Innvierte Tech Transfer) and co-invests in portfolio companies. Closely related as an LP/co-investor rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Asabys Partners social profiles

Digital presence

Asabys Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Asabys Partners leadership team

Management profile

Number of profiles

Profiles16 records

Asabys Partners funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Asabys Partners M&A and investment

M&A and investment

M&A1 record

Investments43 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asabys Partners

What does Asabys Partners do?

Asabys Partners is a Barcelona-based venture capital firm that invests in early-stage and growth-stage healthcare and life-sciences companies across biotech, healthtech, and medtech. It manages investment vehicles including the Sabadell Asabys II fund and the Asabys Innvierte Tech Transfer vehicle, deploying capital alongside hands-on operational partnership to portfolio companies in Europe and beyond.

Is Asabys Partners a public or private company?

Asabys Partners is a private company. It is classified as venture growth investor backed and is currently operating.

When was Asabys Partners founded?

Asabys Partners was founded in 2018. It employs 11 to 50 people.

Where is Asabys Partners based?

Asabys Partners is headquartered in Barcelona, Spain, in the Europe region.

How does Asabys Partners make money?

One revenue line is on record: investment Returns and Management Fees.

Who are Asabys Partners's main competitors?

Direct peers on record are Ysios Capital, Sofinnova Partners, Forbion, Columbus Venture Partners, Mérieux Equity Partners, Panakès Partners and Inkef Capital. Broad incumbents are EQT Life Sciences (formerly LSP) and Bpifrance. CDTI (Centro para el Desarrollo Tecnológico e Industrial) is listed as an others.

Does Asabys Partners have an API?

No public API is recorded for Asabys Partners.

What industry is Asabys Partners in?

Asabys Partners's product category is Venture Capital / Healthcare Investment. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
El ReferenteAllox obtiene 9,4 millones de euros de Asabys, el CDTI y el ICFALLOX closed a $10.5 million (9.4 million euros) funding round led by Asabys, with participation from CDTI and ICF, and appointed Morten Graugaard as independent chairman. The funds will expand its AI platform and drug discovery programs, aiming to accelerate small-molecule therapies for challenging targets.El ReferenteAllox obtiene 9,4 millones de euros de Asabys, el CDTI y el ICFALLOX closed a $10.5 million (9.4 million euros) funding round led by Asabys, with participation from CDTI and ICF, and appointed Morten Graugaard as independent chairman. The funds will expand its AI platform and drug discovery programs, aiming to accelerate small-molecule therapies for challenging targets.El ReferenteAllox obtiene 9,4 millones de euros de Asabys, el CDTI y el ICFALLOX closed a $10.5 million (9.4 million euros) funding round led by Asabys, with participation from CDTI and ICF, and appointed Morten Graugaard as independent chairman. The funds will expand its AI platform and drug discovery programs, aiming to accelerate small-molecule therapies for challenging targets.WebcapitalriesgoALLOX (plataforma fármacos alostéricos) cierra una ronda semilla de $10,5M liderada por Asabys. Participan CDTI, ICFALLOX closed a $10.5M seed round led by Asabys, with participation from CDTI and ICF. The funds will expand its high-throughput bioinformatics and AI platform for discovering allosteric drug targets, and Morten Graugaard was named independent chairman.WebcapitalriesgoPeptomyc cierra una ronda de €5,7M con ICF, Asabys, Aurora, EIC Fund y CDTIPeptomyc closed a €5.7M funding round with ICF, Asabys, Aurora Science, EIC Fund, Laudecum, and CDTI. The funds will complete three clinical trials of OMO-103 and prepare manufacturing for later phases. The company expects to present phase 1b data for pancreatic cancer by end of 2026.AsabysALLOX, a new Centre for Genomic Regulation spin-off, is launched with the support of AsabysALLOX, a spin-off from the Centre for Genomic Regulation, was incorporated and closed an undisclosed pre-seed round from Asabys' Sabadell Asabys II fund. The company develops a platform to map allosteric sites in proteins for drug discovery. It plans a new financial round in 18-24 months.Mpo-magAnaconda Biomed Secures $56 Million in FinancingAnaconda Biomed closed a $56 million financing round led by Omega Funds and FOCO, with participation from Asabys, Ysios Capital, and CDTI. The funds will support product development and the ATHENA pivotal IDE study for its ANA Funnel Catheter. The company targets the large stroke intervention market, where nearly 270,000 mechanical thrombectomy procedures were performed in 2026.Empresas de Capital Riesgo en EspaiPremom raises €15m to transform pregnancy care with molecular diagnosticsiPremom raised €15m in seed funding led by Amadeus Capital Partners, co-led by Asabys and APEX Ventures. The funds will support clinical validation and commercial rollout of its MaiRa platform, which uses a blood test to predict first-trimester pregnancy complications. The company aims to complete validation studies and secure EU and US regulatory approvals.BusinessinsiderOriol Fuertes, CEO de Qida: "Mi objetivo es que quien paga 1.200 euros por nuestros cuidados termine pagando 800"Qida CEO Oriol Fuertes aims to reduce home-care costs from 1,200 to 800 euros per month. The Catalan scaleup serves 13,000 people daily across 25 cities, with annual revenues near 44 million euros. Fuertes plans to launch a hybrid human-sensory product in September.InvestorsinhealthcareSpain: Ona Therapeutics raises US$86.6m Series B to advance First-in-Class ADCs into clinical developmentOna Therapeutics, a Spain-based biopharmaceutical company, closed an oversubscribed US$86.6m Series B financing. The round was co-led by new investors Columbus, with the funds intended to advance first-in-class ADCs into clinical development.